Federated Hermes’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Federated Hermes’s Portfolio SYRS Stock Details SYRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,217	Closed	-$4.37K	–	2288
2022 Q4	$4.37K	Sell	1,217 -22,669	-95%	-$98.4K	﹤0.01%	1939
2022 Q3	$154K	Buy	23,886 +40	+0.2%	+$325	﹤0.01%	1567
2022 Q2	$230K	Sell	23,846 -178	-0.7%	-$1.67K	﹤0.01%	1511
2022 Q1	$286K	Buy	24,024 +7,532	+46%	+$135K	﹤0.01%	1549
2021 Q4	$538K	Buy	+16,492	New	+$668K	﹤0.01%	1462
2020 Q4	–	Sell	-4,705	Closed	-$416K	–	2356
2020 Q3	$416K	Buy	+4,705	New	+$535K	﹤0.01%	1514

Other funds holding SYRS

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Federated Hermes's SYRS Position: Q1 2023 in Review

Federated Hermes sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q1 2023, closing a stake of 1,217 shares — an estimated $4.37K sold.

Federated Hermes first reported a position in SYRS in Q3 2020 and held it in 6 quarters. The position peaked at $538K in Q4 2021. 59 funds tracked by Wall St. Rank hold SYRS as of Q1 2023.

Federated Hermes reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Federated Hermes sold 1,217 Syros Pharmaceuticals, Inc. Common Stock shares in Q1 2023, an estimated $4.37K.
Federated Hermes first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q3 2020 and held it in 6 quarters.
Federated Hermes's Syros Pharmaceuticals, Inc. Common Stock position peaked at $538K in Q4 2021.
59 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q1 2023.

Based on Federated Hermes's 13F filing for Q1 2023, filed 8 May 2023.